Ulcerative colitis

This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

The analysis suggests genetic liability to IBD, particularly Crohn’s disease, may raise the risk of IgA vasculitis. This is relevant for understanding overlapping immune mechanisms and possible shared pathways between...

Understanding which patients are at higher risk for serious complications after IBD surgery can help patients and clinicians weigh risks, plan preoperative optimization, and guide research into preventive strategies.

This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...

Lung inflammation can occur in children with IBD but is uncommon and may be hard to spot because symptoms can be vague or absent. Early recognition matters because imaging, bronchoscopy, and sometimes biopsy help...

Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.

This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...

Fecal incontinence is a distressing symptom that lowers quality of life and appears linked to active disease in UC. Knowing which patients are at higher risk can help clinicians focus assessment and symptom support.

If reliable, an earlier day‑3 PUCAI cutoff could help identify children with flare‑related ASUC who are unlikely to respond to IV steroids and who may benefit from earlier planning for second‑line therapy rather than...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery. The original article is from ANZ Journal of Surgery.

This article suggests a naturally derived compound (isorhamnetin) identified from TCM may reduce inflammation in experimental ulcerative colitis and points to the Nrf2–PTGS2 pathway as a possible mechanism. That could...

Metabolic syndrome appears common in this Tunisian IBD cohort (about one-third). MetS can affect overall health and may influence long-term outcomes for people with IBD, so awareness and cardiometabolic screening may be...

The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.

A simple blood ratio measured before surgery (LCR) may help predict which children with UC are at higher risk of surgical site infection after IPAA, potentially guiding preoperative care.

For patients hospitalized with steroid-refractory ASUC, an effective oral rescue option could be useful when standard biologics are unavailable or contraindicated. The study also highlights that high colonic CMV DNA may...

Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...

The study links a traditional herbal formula to improved colitis in mice and to changes in bile-acid metabolism through the FXR–FGF15 pathway, suggesting a mechanistic route that could inform future preclinical or...

Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...

Blood-based inflammatory ratios like CRP/albumin were associated with higher odds of needing anti‑TNF therapy, colectomy, and longer hospital stays in moderate–severe UC, suggesting potential utility as complementary...

A high-profile athlete describing recovery from ulcerative colitis and Crohn’s disease highlights that people with IBD can regain strength and return to demanding activities—something patients and families may find...

This trial is testing whether a rectally delivered probiotic can change the gut microbiome and promote mucosal healing in people with mild-to-moderate ulcerative colitis (and includes some Crohn's patients). If...

This trial is testing guselkumab (an IL‑23 inhibitor) in a real‑world UC cohort and will measure endoscopic and histologic remission at 48 weeks — outcomes that matter to people managing moderate‑to‑severe ulcerative...

This trial is testing a new investigational antibody (XmAb942) specifically in people with moderately to severely active ulcerative colitis who have not responded to prior therapies. Early‑phase studies determine safety,...

This FDA label update affects people with IBD because tofacitinib is an approved JAK inhibitor for moderately to severely active ulcerative colitis and carries serious safety warnings that may influence treatment choices...

Cure8 found this source from Journal of physiological investigation, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. Open...

This meta-analysis suggests people with IBD face higher risks of major cardiovascular events (heart attack, ischemic heart disease, ischemic stroke), which may matter for monitoring and preventive care. Higher risk...

Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...

Noninvasive ultrasound could make assessment and monitoring of ulcerative colitis quicker and more accessible, including bedside evaluation and better rectal/pouch assessment with TPUS—potentially reducing reliance on...

This review summarizes many observational studies to identify dietary and environmental factors that may influence the risk of developing ulcerative colitis, which could help guide future research and prevention efforts...

The review suggests matrine and oxymatrine reduce inflammation and oxidative stress in animal UC models, pointing to potential new therapeutic approaches. People with UC may want to know about directions in preclinical...

Diet is a modifiable factor many people with IBD try to use to feel better. This review summarizes current evidence that a Mediterranean-style eating pattern may help quality of life and is linked to lower inflammation...

Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Colorectal cancer, and Procedures and surgery. The original article is from Gastroenterology report.

This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...

The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...

The case suggests that blocking IL-4/IL-13 (with dupilumab) might rarely trigger Th17-predominant colonic inflammation presenting as ulcerative colitis; patients and clinicians should be alert for new GI symptoms after...

Links between IBD genetic risk and specific adult tissue lesion contexts help researchers understand which cell types and tissue programs may mediate inherited susceptibility. That can guide future biomarker and...

New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...

Antibiotics can change the gut microbiome in ways that may raise IBD risk or worsen disease for some people. Knowing which antibiotic classes and approaches may be less harmful could help patients and clinicians reduce...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Genetic...

This trial explores whether oral ozanimod can induce and maintain remission in children and adolescents with moderate to severe ulcerative colitis who have not responded to standard therapies. Pediatric-specific evidence...

Patients with UC often take multiple medicines that rely on CYP enzymes. This study is checking if afimkibart affects how those drugs are processed, which could matter for safety or dosing if the drug proceeds in...

A validated pre-endoscopic model could help estimate UC disease extent before colonoscopy, aiding clinical triage and planning without replacing endoscopy.

If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...

Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...

This global survey shows that people with IBD prioritize symptom relief and psychological well-being over treatment features like administration route or speed of onset. That matters for shared decision-making, trial...

If organoid transplantation can be translated to people, it could offer a new way to repair inflamed colonic lining and promote mucosal healing when current therapies are insufficient. The approach also highlights links...

If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.